ABC-NP - - An Aquaretic and Natriuretic Peptide Without Vasodilatory Properties

Reference #:

2006-159

Inventors/Contributors

Horng H. Chen M.D., John C. Burnett Jr. M.D.

Description

The natriuretic peptide family consists of natural hormones involved in the maintenance of fluid and sodium levels through their interactions with the heart and kidneys. Mayo Clinic researchers have developed a novel natriuretic peptide (ABC) which is made up of a unique amino acid sequence designed to preferentially target the kidney to preserve its function and protect it from damage/disease. ABC has been shown to be effective in animal models of cardiorenal disease and Mayo is currently developing the compound to a phase I clinical trial. Application A biological therapy for treatment of cardiorenal conditions including contrast induced nephropathy, acute renal failure, and renal ischemia associated with cardiac bypass surgery. Stage of Development Preclinical efficacy studies have been completed in animal models. Preclinical toxicology, formulation, and assay work is ongoing. Current timeline is to secure an IND for intravenous delivery of ABC in early 2011. A formulation for oral delivery of ABC is currently being tested in animal models.

Patent Status

Pending